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Abstract Background In smokers treated with fibrinoly-
sis for ST-elevation myocardial infarction (STEMI) a
paradoxical beneficial short-term outcome has been
reported. This was attributed to favorable clinical and
angiographic baseline variables and a better response to
fibrinolysis. During follow-up infarct artery reocclusion is
an important prognosticator. We studied the effects of
smoking on reocclusion and long-term cardiac outcome
after successful fibrinolysis. Methods In the Antithrom-
botics in the Prevention of Reocclusion In COronary
Thrombolysis trials (APRICOT-1 and -2) 499 STEMI
patients with an open infarct artery\48 h after fibrinolysis
received randomized antithrombotic treatment until 3-
month follow-up angiography. Five-year clinical follow-up
was complete. Results Current smokers (317 patients, 64%)
had favorable clinical (age 54 vs. 60 years, P \ 0.01) and
angiographic (single vessel disease 61% vs. 49%,
P = 0.02) baseline characteristics. Reocclusion rates were
21% (67/317) in smokers versus 32% (59/182) in non-
smokers (P \ 0.01). Five-year infarct-free cardiac survival
did not differ: 82% vs. 85%. Reocclusion (HR 2.41, 95%CI
1.05–5.56, P = 0.04) independently predicted cardiac
mortality. Smoking was independently associated with a
reduced risk of reocclusion (OR 0.58, 95%CI 0.37–0.91,
P = 0.02), but not with improved 5-year cardiac outcome
(HR 1.34, 95%CI 0.79–2.25, P = ns). Conclusions After
successful fibrinolysis, smoking is independently associ-
ated with a more than 40% reduced risk of reocclusion,
which is an independent predictor of adverse outcome.
However, even with more favorable baseline characteris-
tics smokers did not have improved 5-year cardiac outcome
in this low-risk population.
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Introduction
Many epidemiological studies have shown that cigarette
smoking is associated with an increased risk of myocardial
infarction and death from coronary artery disease, includ-
ing sudden death [1–3]. However, after acute myocardial
infarction short-term clinical outcome in smokers is more
favorable than in non-smokers. In patients treated with
fibrinolysis for acute myocardial infarction this so-called
‘‘smoker’s paradox’’ has been attributed to more favorable
clinical and angiographic baseline characteristics in
smokers [4–6]. Several studies reported higher rates of
good early antegrade epicardial flow (Thrombolysis In
Myocardial Infarction (TIMI) 3 flow) in smokers [7],
suggesting a better response to fibrinolysis [5, 6, 8–11].
After successful fibrinolysis, outcome is strongly related
to reocclusion of the infarct artery, which portends an
increased risk of death, reinfarction and revascularization
[12–14]. Notably, most reocclusions occur without clinical
reinfarction [12–14]. Even in these cases, reocclusion has
adverse impact on recovery of left ventricular function
[15]. Previously we have shown that reocclusion is a strong
predictor of 10-year cardiac mortality, independent of left
P. C. Kievit (&)  M. A. Brouwer  W. R. M. Aengevaeren 
F. W. A. Verheugt
Heartlungcenter, 670 Department of Cardiology, Radboud
University Nijmegen Medical Center, P.O. Box 9101,
6500 HB Nijmegen, The Netherlands
e-mail: p.kievit@cardio.umcn.nl
G. Veen
VU University Medical Center, Amsterdam, The Netherlands
123
J Thromb Thrombolysis (2009) 27:385–393
DOI 10.1007/s11239-008-0238-6
ventricular ejection fraction, and even when presenting
without signs of reinfarction or recurrent ischemia [16].
Data on the risk of reocclusion in smokers are scarce and
conflicting. In GUSTO-1 current smokers had a lower risk
of in-hospital reocclusion than non-smokers [5], whereas
no difference was observed in the TAMI trials [6].
In the angiographic follow-up studies APRICOT-1 and
APRICOT-2 the effect of different antithrombotic regi-
mens on 3-month reocclusion was studied in patients with a
patent infarct artery after fibrinolysis [17, 18]. For the
present analysis we assessed differences in clinical and
angiographic baseline variables between smokers and non-
smokers and the effect of smoking on reocclusion and
short- and long-term cardiac outcome.
Methods
Protocol
The study protocols of the APRICOT-1 (1987–1991) and
APRICOT-2 (1995–2000) trials have been reported in
detail previously [17, 18].
Patients received fibrinolysis for suspected acute ST-
elevation myocardial infarction (STEMI) followed by
infusion of unfractionated heparin. In the case of clinical
and/or electrocardiographic signs of reperfusion, stable
patients were asked informed consent to undergo coronary
angiography within 48 h after fibrinolysis. Patients with a
patent infarct artery were eligible for the study.
In the APRICOT-1 trial patients were randomly allo-
cated to one of three arms: blinded treatment with either
325 mg of aspirin or placebo, or open-label coumadin
including continued heparinization until the target INR
(2.8–4.0) was reached. After follow-up angiography the
study medication was discontinued and, unless they had an
indication for oral anticoagulation, all patients received
aspirin based on the ISIS-2 results [19], which became
available shortly after initiation of the trial.
In APRICOT-2 patients were randomized to two arms.
In one arm patients continued treatment with aspirin 80 mg
with discontinuation of heparin at 48 h. In the other arm
coumadin was added to aspirin 80 mg with continuation of
heparin until moderate-intensity anticoagulation (target
INR 2–3) was achieved.
Cardiac catheterization
Follow-up angiography was scheduled at 3 months to
assess reocclusion, the primary endpoint of the APRICOT
trials. In APRICOT-1 reocclusion was defined as ECSG
grade 4 (91–99% diameter stenosis, no complete filling
within 3 cycles) or grade 5 stenosis (total occlusion with or
without collateral filling) [17]. In APRICOT-2 the defini-
tion of reocclusion was TIMI flow grade 2 or less [18].
Anatomical reocclusions were defined as ECSG grade 5
and TIMI flow 0 or 1, respectively. An ischemia-guided
revascularization strategy was adopted [17]. If coronary
angioplasty was performed before the planned repeat
angiography, the patency status of the infarct artery before
wire crossing was scored as follow-up endpoint. At base-
line angiography quantitative coronary angiography (QCA)
of the culprit lesion was performed, providing a precise
estimation of the diameter stenosis with low intra- and
interobserver variability [20]. For this analysis the optimal
single projection with the most severe measured stenosis
was used. Morphology of the culprit lesion was scored
according to the Ambrose criteria [21].
Clinical follow-up
Five-year clinical and survival data were collected from
medical charts, civil registries, or by written or telephone
contact with the patient, relatives or the general practi-
tioner. All deaths were confirmed by civil registry data.
Patients participating in APRICOT-2 were systematically
questioned about their smoking behavior at follow-up
visits. Cardiac mortality was defined based on the infor-
mation of the treating physician, and only in the case of a
confirmed cardiac diagnosis. An instantaneous death, for
which the cause could not be determined with certainty,
was scored as a death of cardiac origin. Confirmed vascular
deaths (strokes, aneurysms, aortic dissections, pulmonary
embolisms) were not considered as cardiac death. If the
cause was unknown/uncertain and death did not occur
instantaneously it was classified as ‘cause undetermined’.
An event was qualified as reinfarction (infarct artery rela-
ted) when at least 3 of the 4 GUSTO-1 criteria were met
[22]: (1) recurrent ischemic symptoms lasting [15 min
after resolution of symptoms of the index infarction, (2)
new ST-T wave changes or new Q-waves in the same area
as the index infarction, (3) a second elevation in cardiac
enzymes over the normal upper limit (or by a further 20%
if already elevated), and (4) reocclusion of the infarct
artery. Reinfarctions not meeting these electrocardio-
graphic criteria or attributed to a different coronary artery
at urgent repeat angiography were considered to be not
infarct artery related.
Recurrent ischemic events were defined as the combi-
nation of reinfarction, unstable angina and recurrent
angina with documented ischemia at stress testing.
Revascularization of the infarct artery was scored in the
case of percutaneous coronary intervention (PCI) of the
index infarct vessel or coronary artery bypass grafting
(CABG).
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Statistics
Statistical analysis was performed with SPSS 14.0 (SPSS
Inc. 2005, Chicago, USA). For comparison of continuous
variables the Student’s t-test and Mann–Whitney U-test
were used whenever appropriate. Comparisons of propor-
tions between groups were performed with the v2-test.
Statistical significance was defined as a two-sided P-value
\0.05. Multivariable logistic regression analysis was used
to determine the association between smoking status at
baseline and reocclusion. Variables included in the model
were baseline characteristics that were imbalanced between
smokers and non-smokers (P \ 0.10, see ‘‘Results’’), pre-
dictors of reocclusion at univariable analysis and the
antithrombotic regimen (prespecified).
Long-term survival analysis was performed according to
Kaplan and Meier, using the log rank test for comparison
between groups. To determine the association between
smoking status at baseline and 5-year (infarct-free) cardiac
survival multivariable Cox-regression analysis using for-
ward logistic regression was performed. TIMI risk score
variables [23] and the antithrombotic regimen were pro-
spectively chosen to be included in the model. Baseline
characteristics that were imbalanced between smokers
and non-smokers and univariate predictors of long-term
outcome completed the model.
Results
Of the 558 patients enrolled in the APRICOT-1 and APRI-
COT-2 trials the current report includes the 499 patients with
complete angiographic follow-up (Fig. 1). Patients without
follow-up angiography were significantly older (62 ± 8 vs.
56 ± 10 years, P \ 0.01), more often female (33% vs. 17%,
P \ 0.01), and tended to have more often a history of previous
myocardial infarction (16% vs. 9%, P = 0.09). The propor-
tion of current smokers at enrollment did not differ from
patients with angiographic follow-up (59% vs. 64%, P = ns).
Baseline characteristics
At baseline 317 (64%) of the 499 patients were current
smokers. Baseline characteristics of smokers and non-
smokers are listed in Table 1. With respect to clinical
characteristics smokers were younger, and had less often a
history of prior myocardial infarction, diabetes, hyperten-
sion or a positive family history.
At baseline angiography smokers had less severe residual
infarct related stenoses, more smooth infarct lesions and
more often single vessel disease. Smokers tended to have
more often an infarction related to the left coronary artery.
Peak CK-levels were higher in smokers, but baseline ejection
fraction did not differ from non-smokers.
APRICOT-2
308 patients randomized
Exclusion: n = 16 
No ECSG 1-3 
(angiographic committee) 
Exclusion: n = 34 
No TIMI 3 flow 
(core lab) 
Inclusion
n = 284
Inclusion
n = 274
No 2nd angiogram  n = 36 
Refusal n = 28 
Death n = 2 
CABG n = 6 
Total
inclusion
n = 558
No 2nd angiogram  n = 23 
 Refusal n = 19 
 Death n = 1 
 CABG n = 3
APRICOT-1
2nd angiography 
n = 248
Long-term clinical follow-up 
Total
2nd angiography 
n = 499
APRICOT-2
2nd angiography 
n = 251
APRICOT-1
300 patients randomized 
Fig. 1 Flow chart showing
number of patients from
APRICOT-1 and APRICOT-2
excluded and number remaining
with follow-up angiography and
long-term clinical follow-up
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Reocclusion
Follow-up angiography was performed after a median of 89
(interquartile range 64–97) days. Reocclusion rates were
21% (67/317) in smokers versus 32% (59/182) in non-
smokers: RR 0.56, 95%CI 0.37–0.84, P \ 0.01. When only
anatomical reocclusions were considered the rates were
16% (49/317) and 25% (45/182), respectively: RR 0.56,
95%CI 0.35–0.88, P = 0.01.
Exploratory analysis showed that the reduced risk of
reocclusion observed in smokers in the overall study pop-
ulation was generally consistent across many different
subgroups (Fig. 2). No significant interaction (P \ 0.01)
between the effect of smoking and any of the subgroup
variables was observed.
At multivariable analysis smoking was independently
associated with a markedly reduced risk of reocclusion of
the infarct artery: OR 0.58, 95%CI 0.37–0.91, P = 0.02. If
only anatomical reocclusions (ECSG grade 5, TIMI 0,1)
were considered the adjusted odds ratio was 0.59, 95%CI
0.35–0.97, P = 0.04. Baseline culprit stenosis severity also
independently predicted reocclusion: OR 1.07, 95%CI
1.05–1.09, P \ 0.01.
Compared with placebo, antithrombotic treatment with
aspirin alone (325 mg or 80 mg, n = 221; OR 0.51, 95%CI
0.27–0.98, P = 0.04) or in combination with coumadin
(n = 123; OR 0.29, 95%CI 0.13–0.65, P \ 0.01) was
independently associated with a reduced risk of reocclu-
sion. Coumadin alone (n = 81; OR 0.71, 95%CI 0.33–
1.53, P = ns) was not superior to placebo.
Clinical outcome—short-term
Table 2 lists the 3-month rates of recurrent ischemic events
and revascularizations in smokers and non-smokers.
Reinfarction rates were similar in smokers and non-
smokers. Smokers had lower rates of unstable angina and
revascularization. The proportion of patients with recurrent
ischemic events who underwent revascularization was 43%
(39/90) in smokers and 49% (37/75) in non-smokers
(P = ns).
Clinical presentation of reocclusion
Reocclusion presented with reinfarction in 21% (26/126) of
cases. The proportion of reocclusions presenting with
reinfarction did not differ between smokers and non-
smokers: 21% (14/67) vs. 20% (12/59), P = ns. In both
groups the proportion of reocclusions occurring with
recurrent ischemic events was also similar: 51% (34/67) vs.
58% (34/59), P = ns.
Of the patients with reocclusion 27% (34/126) under-
went revascularization at the time of follow-up angiography
with no difference between groups: 25% (17/67) in smokers
versus 29% (17/59) in non-smokers (P = ns).
Clinical outcome—long-term
Data on 5-year survival were complete in all 499 patients
(100%). The long-term use of antithrombotic agents (99%),
beta-blockers (70%), ACE-inhibitors (45%) and statins
(70%) did not differ between smokers and non-smokers.
Table 1 Baseline characteristics
Smokers
(n = 317)
Non-smokers
(n = 182)
P
Clinical characteristics
Men 260 (82) 154 (85) 0.46
Age (years) 54 ± 9 60 ± 9 \0.01
Previous angina 161 (51) 106 (58) 0.28
Previous myocardial
infarction
18 (6) 25 (14) \0.01
Diabetes 11 (4) 15 (8) 0.02
Hypertension 68 (22) 57 (31) 0.02
Family history of CAD 107 (34) 85 (47) \0.02
Hypercholesterolemia 213 (67) 123 (68) 0.93
Time symptoms—
fibrinolysis (h)
2.2 ± 1.2 2.2 ± 1.2 0.87
Peak creatine kinase
(units/l)
1116
(563–2146)
862
(401–1825)
\0.01
Antithrombotic regimen
Coumadin 60 (19) 21 (12) 0.06
Aspirin 325 mg 57 (18) 36 (20)
Placebo 52 (16) 22 (12)
Aspirin 80 mg 71 (22) 57 (31)
Aspirin 80 mg
+ Coumadin
77 (24) 46 (25)
Angiographic characteristics
Infarct artery
LAD 138 (44) 68 (37) 0.06
LCX 54 (17) 23 (13)
RCA 125 (39) 91 (50)
Culprit stenosis severity
(%, QCA)
58.8 ± 14 61.6 ± 12 0.02
Culprit lesion morphology
Smooth 204 (64) 94 (52) \0.01
Complex 113 (36) 88 (48)
Single vessel disease 192 (61) 90 (49) 0.02
Left ventricular ejection
fraction (%)
52.4 ± 11 53.5 ± 10 0.29
Data are presented as number (%) of subjects for discrete variables and
mean ± standard deviation for continuous variables, except for peak
creatine kinase which is presented as median (interquartile range).
CAD = coronary artery disease; LAD = left anterior descending
coronary artery; LCX = left circumflex coronary artery; RCA = right
coronary artery; QCA = quantitative coronary angiography
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During follow-up 38 deaths were observed, 29 (76%) of
which were cardiac. Five-year survival was 93% in smokers
and 92% in non-smokers (P = ns). Cardiac survival did not
differ either: 94 and 94%, respectively. Cardiac survival
free from infarct artery related reinfarction was 82% in
smokers and 85% in non-smokers (Fig. 3, P = ns).
Including revascularizations event-free 5-year survival did
not differ either: 58 and 54%, respectively (P = ns).
At multivariable Cox-regression analysis reocclusion
(HR 2.41, 95%CI 1.05–5.56, P = 0.04) and left ventricular
ejection fraction (HR 0.93, 95%CI 0.90–0.97, P \ 0.01)
independently predicted 5-year cardiac mortality. Smoking
was neither predictive of long-term cardiac survival (HR
1.42, 95%CI 0.55–3.63, P = ns) nor of infarct-free cardiac
survival (HR 1.34, 95%CI 0.79–2.25, P = ns).
Variable Odds ratio (95% CI) 
Overall 0.56 (0.37-0.84) 
Sex
 Male 
 Female 
0.61 (0.39-0.95) 
0.35 (0.12-1.03) 
Age
> 65 yr 
 < 65 yr 
1.28 (0.54-3.04) 
0.47 (0.29-0.76) 
Previous MI 
 yes 
 no 
0.26 (0.06-1.11) 
0.62 (0.40-0.96) 
Diabetes 
 yes 
 no 
1.14 (0.22-5.84) 
0.54 (0.34-0.87) 
Hypertension 
 yes 
 no 
0.45 (0.19-1.07) 
0.57 (0.36-0.92) 
Family history of CAD 
 yes 
 no 
0.59 (0.30-1.13) 
0.53 (0.31-0.90) 
Cholesterol  
> 5.0 mmol/L 
 < 5.0 mmol/L 
0.61 (0.38-0.99) 
0.42 (0.18-0.96) 
Infarct artery 
 LAD 
 LCX 
 RCA 
0.66 (0.35-1.25) 
0.22 (0.07-0.65) 
0.63 (0.33-1.18) 
Culprit stenosis severity (QCA) 
> 50 % 
 < 50 % 
0.60 (0.38-0.94) 
0.34 (0.08-1.37) 
Culprit lesion morphology 
 smooth 
 complex 
0.51 (0.30-0.86) 
0.57 (0.29-1.13) 
Extent of CAD 
 single vessel disease 
 multi vessel disease 
0.55 (0.31-0.97) 
0.59 (0.33-1.08) 
Ejection fraction 
> 50 % 
 < 50 % 
0.56 (0.33-0.93) 
0.53 (0.26-1.09) 
Antithrombotic regimen 
 Coumadin 
 Aspirin 325 mg 
 Placebo 
 Aspirin 80 mg 
 Aspirin 80 mg + Coumadin 
0.19 (0.06-0.55) 
0.61 (0.23-1.57) 
0.44 (0.16-1.25) 
0.86 (0.40-1.86) 
0.61 (0.23-1.65) 
0.0  0.5     1.0        1.5             2.0 
smoking better non-smoking better
MI = myocardial infarction; CAD = coronary artery disease; LAD = left anterior descending coronary artery; LCX = left 
circumflex coronary artery; RCA = right coronary artery: QCA = quantitative coronary angiography  
Fig. 2 Subgroup analyses on
the odds of reocclusion in
smokers and non-smokers after
successful fibrinolysis
Table 2 Three-month clinical outcome
Smokers
(n = 317)
Non-smokers
(n = 182)
P
Recurrent ischemic events 90 (28) 75 (41) \0.01
Reinfarctiona 20 (6) 14 (8) 0.56
Unstable angina 49 (16) 46 (25) \0.01
Recurrent angina with
documented ischemiab
21 (7) 15 (8) 0.50
Revascularizationa 43 (14) 41 (23) 0.01
PCI 41 (13) 40 (22) \0.01
CABG 5 (2) 4 (2) 0.62
Data are presented as number of subjects and proportions (%) per
study group. Patients may have had events in more than one category
a Infarct artery related
b Positive stress test
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Discussion
This is one of the largest reports on the impact of smoking
on reocclusion in patients with a patent infarct artery after
fibrinolysis for STEMI. Smoking was independently asso-
ciated with a markedly reduced risk of reocclusion at 3
months. However, even with more favorable clinical and
angiographic baseline characteristics, smokers did not have
improved 5-year cardiac outcome.
Baseline characteristics of smokers after successful
fibrinolysis
In previous studies after fibrinolysis the paradoxical ben-
eficial short-term outcome of smokers has been attributed
to more favorable clinical and angiographic baseline
characteristics and a better response to fibrinolytic therapy
[4–6, 8–11]. Consistent with the latter observation we
found a rate of current smokers in patients after successful
fibrinolysis which is considerably higher than reported in
the overall fibrinolysis population in contemporary mega-
trials: 64% vs. 44% [22, 24]. Also in our study smokers had
a more favorable clinical risk profile with younger age and
less concomitant risk factors for coronary artery disease. At
baseline angiography smokers had less extensive coronary
artery disease with a higher rate of single vessel disease,
less severe residual infarct related stenoses, and more
smooth infarct lesions.
Whereas in previous trials smokers most often had
infarctions related to the right coronary artery [4, 5, 8], left
coronary artery infarctions predominated in smokers in our
study. Besides a different timing of angiography (24 h vs.
90 min), this may be explained by the inclusion of only
patients with a patent infarct artery. Smoking status pre-
dicts TIMI 3 flow independent of the infarct artery [11].
Smoking and reocclusion
Given the strong relationship between reocclusion and
outcome after successful fibrinolysis [12–14], previous
studies addressed the risk of reocclusion in smokers in
search for potential mechanisms explaining their favorable
outcome. Results of these studies have been conflicting. In
GUSTO-1 5–7 days follow-up angiography was performed
in 75% of patients with a patent infarct artery (TIMI 2,3) at
90-min angiography who were randomized to undergo a
second angiogram [25]. The unadjusted reocclusion rate
(TIMI 0,1) was significantly lower in current smokers than
in non-smokers: 2.7% vs. 7.7% [5]. However, in the TAMI
trials predischarge reocclusion rates in the subgroup of
patients who did not undergo acute angioplasty were sim-
ilar in smokers and non-smokers: 7.3% vs. 9.3% [6]. After
primary angioplasty (half of patients receiving stents)
crude 7-month reocclusion rates did not differ either: 7.7%
vs. 9.3% [26].
The APRICOT-trials were specifically designed for the
study of reocclusion in patients with a patent infarct artery
after fibrinolysis and included mandatory follow-up angi-
ography, which was performed in 89% of patients (Fig. 1).
Whereas previous studies only reported unadjusted reoc-
clusion rates, we found a more than 40% reduced risk of
reocclusion in smokers, even after multivariable analysis.
The reduced risk was observed consistently across many
different subgroups and occurred independent of anti-
thrombotic regimen and culprit stenosis severity, a known
strong predictor of reocclusion in this setting [27–29]. The
majority of reocclusions have been shown to occur without
clinical reinfarction [12–14]. In our study reocclusion
occurred without clinical reinfarction in almost 80% of
cases, while 46% of patients with reocclusion did not
experience recurrent ischemic events. The clinical presen-
tation of reocclusion did not differ between smokers and
non-smokers.
The mechanism behind the reduced risk of reocclusion
in smokers may be related to the nature of coronary
occlusions in smokers. Coronary lesions in smokers, with
their younger age and less extensive coronary artery dis-
ease, are presumably more thrombotic than atherogenic in
nature [6]. Thrombotic lesions are more susceptible to
regression of the culprit stenosis, which has been shown to
occur before hospital discharge in patients treated with
fibrinolysis [30]. Whereas stenosis severity between
smokers and non-smokers did not differ in studies with 90-
min angiography [5, 6, 9, 10], a lower diameter stenosis has
been reported in smokers before discharge [6]. In our study
with 24-h angiography smokers also had a lower culprit
Infarct-free cardiac survival
0 1 2 3 4 5
0
25
50
75
100
years
Pe
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en
t s
ur
vi
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l
Smokers
Non-smokers 
n = 317  278          270    264            262     254 
n = 182  167          163    159            152     150 
*Patients dying from non-cardiac causes were censored at the time of death 
%
Patients at risk*:
log-rank
p = ns
Fig. 3 Estimated cardiac survival free from infarct artery related
reinfarction in smokers and non-smokers after successful fibrinolysis
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diameter stenosis. These findings suggest that regression of
the culprit stenosis in the first days after fibrinolysis may be
more pronounced in smokers than in non-smokers. Reso-
lution of thrombus material on a primarily non-atherogenic
lesion may reduce the residual culprit stenosis and thereby
the risk of reocclusion.
Smoking and clinical outcome
A lower risk of short-term mortality in smokers has been
reported in a broad range of patients after acute myocardial
infarction: after fibrinolysis [4–6, 9, 10, 31] after primary
angioplasty [26] and in patients with heart failure or left
ventricular dysfunction [32]. In most [4–6, 9, 10, 26], but not
all [31] of these reports, the survival benefit was attributed to
the favorable clinical and angiographic baseline character-
istics in smokers. In our study smokers also had a more
favorable clinical and angiographic risk profile. Moreover,
smokers had a more than 40% reduced risk of reocclusion.
As previously observed with respect to 10-year cardiac
outcome in APRICOT-1 [16], also in the present study
reocclusion was independently associated with a more than
twofold increased risk of long-term cardiac mortality.
Nevertheless, no survival difference was found between
smokers and non-smokers. Notably, both in smokers and
non-smokers most patients had preserved left ventricular
function (mean ejection fraction [ 50%). This may explain
the low 5-year cardiac mortality rate (about 6%) in our study
and also that, as a consequence, the moderate absolute dif-
ference in risk of reocclusion (11%) was not large enough to
yield a difference in survival between smokers and non-
smokers. Our findings resemble observations from GUSTO
V [24], in which study a significant reduction in reinfarction
did not result in improved short-term survival, despite the
strong independent relationship between reinfarction and
mortality after fibrinolysis [33]. Analogous to that finding, a
reduced risk of reocclusion may not automatically confer
improved outcome, especially in a low-risk population.
Besides the adverse impact on long-term survival,
reocclusion also impairs left ventricular recovery [15]. The
lower reocclusion rate in smokers may therefore confer a
beneficial effect on remodeling and a lower risk to develop
heart failure. Although we did not assess patients’ func-
tional status, admissions for heart failure were infrequent
and did not differ between groups.
Several studies have reported lower reinfarction rates in
smokers as compared to non-smokers [4, 5, 26, 31, 32]. In
one study current smoking was independently associated
with a lower risk of reinfarction 42 days after fibrinolysis
[4]. Despite the independently reduced risk of reocclusion
in smokers in our study, the risk of reinfarction at 3 months
did not differ from non-smokers. The proportion of reoc-
clusions presenting with reinfarction was only about 20%,
and did not differ between smokers and non-smokers. With
the 11% absolute difference in reocclusion rate between
groups and the overall 3-month reinfarction rate of only 7%
this did not result in a difference in risk of reinfarction
between smokers and non-smokers. Notably, after fibri-
nolysis about half of the reinfarctions occur in the first 48 h
[33]. The design of our study, with inclusion of only
clinically stable patients with a patent infarct artery at 24–
48 h, precluded detection of a difference in the rate of these
very early reinfarctions.
Non-smokers had a higher rate of early recurrent
ischemic events, and, as a result of the ischemia-guided
revascularization strategy, more often underwent early
revascularization. Whereas routine revascularization early
after fibrinolysis may be preventive of recurrent events
[34], ischemia-guided revascularization was not associated
with improved outcome in this study.
Data on smoking cessation during follow-up were only
available in patients from APRICOT-2. About half of the
smokers stopped immediately at the time of the index
infarction and did not resume smoking. Despite the strong
association between smoking cessation after acute myo-
cardial infarction and improved outcome in past trials [35,
36], 5-year infarct free survival in these ‘‘quitters’’ did not
differ from patients who continued to smoke or non-
smokers (data not shown).
Limitations
Our observations apply to a well defined, but selected
group of low-risk patients. Although this is a post hoc
pooled analysis from two trials, the study protocols were
almost identical and the reduced risk of reocclusion in
smokers was present in both trials and consistent across
many different subgroups.
The definition of reocclusion differed between APRICOT-
1 and APRICOT-2. However, if only anatomical reocclusions
(ECSG grade 5 and TIMI 0,1) were considered the observed
effect of smoking on reocclusion did not change.
Five-year survival data were complete in all patients and
all deaths were confirmed by civil registry data. Despite
strenuous efforts to obtain detailed information about the
circumstances of death in all deceased patients and a strict
definition of cardiac mortality, the adjudication of mortal-
ity may sometimes have been limited by the recollection of
patients’ relatives and general practitioners. In addition, we
cannot exclude that non-fatal events may not have been
reported.
The fact that APRICOT-2 was performed a decade later
than APRICOT-1, in an era in which the use of ACE-
inhibitors and statins became widespread, does not seem to
have affected our results. To date treatment of patients after
fibrinolysis is more aggressive than in the APRICOT trials,
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with higher rates of revascularization and improved anti-
thrombotic therapy (new anticoagulants, clopidogrel). In
the current era the risk of reocclusion and outcome in
smokers after fibrinolysis may therefore be different than
observed in this study.
Conclusions
Also in patients with a patent infarct artery within 48 h
after fibrinolysis, smokers have more favorable clinical and
angiographic baseline characteristics than non-smokers.
Smoking was independently associated with a more than
40% reduced risk of reocclusion. However, although
reocclusion independently predicted cardiac survival, the
markedly reduced risk of reocclusion in smokers did not
lead to improved outcome in this population of patients
with a low a priori risk of adverse events.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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